Recruiting

Phase 1

ZanzalintinibStudy of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors

Sponsor:

Exelixis

Code:

NCT05176483

Conditions

Renal Cell Carcinoma (RCC)

Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Urothelial Carcinoma (UC)

Solid Tumor

Hepatocellular Carcinoma (HCC)

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Zanzalintinib

Nivolumab

Ipilimumab

Nivolumab

Study Details

Brief summary:

This is a multicenter Phase 1b, open label, dose-escalation and cohort-expansion study, evaluating the safety, tolerability, pharmacokinetics (PK), preliminary antitumor activity, and effect of biomarkers of zanzalintinib administered alone, and in combination with nivolumab (doublet), nivolumab + ipilimumab (triplet) and nivolumab + relatlimab (triplet) and in combination with docetaxel and prednisone in participants with advanced solid tumors. In addition, the study will evaluate the effect of multiple dose administration of zanzalintinib on the single-dose pharmacokinetics of sensitive CYP3A4, CYP2C9, CYP2C19, or CYP1A2 substrates in participants with advanced solid tumors.

In the Expansion Stage, the safety and efficacy of zanzalintinib as monotherapy and in combination therapy will be further evaluated in tumor-specific Expansion Cohorts.

Conditions

Renal Cell Carcinoma (RCC)

Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Urothelial Carcinoma (UC)

Solid Tumor

Hepatocellular Carcinoma (HCC)

Study ID

NCT05176483

Start date

Dec 14, 2021

Status verified date

Jul, 2026

Completion date

Jun 28, 2030

Anticipated

Primary completion date

Jan 31, 2027

Anticipated

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Key Inclusion Criteria:

Cytologically or histologically confirmed solid tumor that is unresectable, locally advanced or metastatic.
Dose-Escalation Cohorts: Participants with a solid tumor that is unresectable or metastatic and for which life-prolonging therapies do not exist or available therapies are intolerable or no longer effective.
Expansion Cohort 1 (ccRCC): Participants with unresectable advanced or metastatic RCC with a clear cell component who have not received prior systemic therapy.

Note: Prior non-vascular endothelial growth factor (VEGF) targeted adjuvant or neoadjuvant is allowed if disease recurrence occurred 6 months after the last dose.
Expansion Cohort 2 (ccRCC): Participants with unresectable advanced or metastatic RCC with a clear cell component.

Must have radiographically progressed after a combination therapy consisting of a Programmed Cell Death Protein 1 (PD-1)/Programmed death-ligand 1 (PD-L1) targeting monoclonal antibody (mAb) with a Vascular endothelial growth factor (receptor) tyrosine kinase inhibitor (VEGFR-TKI) or a PD-1 targeting mAb with a CTLA-4 mAb as the preceding line of therapy.
Must have received no more than one prior systemic anticancer therapy for unresectable advanced or metastatic renal cell carcinoma.
Expansion Cohort 3 (mCRPC): Men with metastatic adenocarcinoma of the prostate.

Must have progressed during or after one novel hormone therapy (NHT) given for castration-sensitive locally advanced (T3 or T4) or metastatic castration-sensitive prostate cancer (CSPC), M0 CRPC, or mCRPC.
Expansion Cohort 4 (UC, ICI-naive): Participants with histologically confirmed unresectable, locally advanced or metastatic transitional cell carcinoma of the urothelium (including the renal pelvis, ureter, urinary bladder, or urethra).

Must have progressed during or after prior first-line platinum-based combination therapy, including participants who received prior neoadjuvant or adjuvant platinum-containing therapy with disease recurrence < 12 months from the end of last therapy.
Must have received no more than 1 prior line of systemic anticancer therapy for unresectable, locally advanced or metastatic disease.
Expansion Cohort 5 (post enfortumab vedotin \[EV\] and ICI): Participants with histologically confirmed unresectable, locally advanced or metastatic predominant urothelial carcinoma.

Progressive disease following prior EV or ineligible for EV, and progression following prior PD-1/PD-L1 inhibitor or ineligible for PD-1/PD-L1 inhibitor.
Prior receipt of platinum-based therapy allowed but not required.
Prior therapy with other agents allowed but not required.
Expansion Cohort 6 (nccRCC): Participants with unresectable advanced or metastatic nccRCC of the following subtypes: Papillary, unclassified RCC, and translocation-associated, Fumarate Hydratase (FH) deficient and Succinate Dehydrogenase (SDH) deficient. Among the eligible histologic subtypes, sarcomatoid features are allowed.

No prior systemic anticancer therapy is allowed except adjuvant or neoadjuvant therapy if disease recurrence occurred at least 6 months after the last dose.
Expansion Cohort 7 (HCC): Participants with locally advanced, or metastatic and/or unresectable HCC that is not amenable to curative treatment or locoregional therapy.
Expansion Cohort 8 (NSCLC): Participants with Stage IV non-squamous NSCLC with positive PD-L1 expression (tumor proportion score \[TPS\] 1-49%) and without prior systemic anticancer therapy for metastatic disease.
Expansion Cohort 9 (NSCLC): Participants with Stage IV non-squamous NSCLC who have radiologically progressed following treatment with one prior immune checkpoint inhibitor (anti-PD-1 or anti-PD-L1) for metastatic disease.
Expansion Cohort 10 (CRC): Participants with histologically confirmed unresectable, locally advanced, or metastatic adenocarcinoma of the colon or rectum.
Expansion Cohort 11 (HNSCC): Participant with inoperable, refractory, recurrent or metastatic HNSCC of the oral cavity, oropharynx, hypopharynx, and larynx. PD-L1 combined positive score (CPS) ≥1.
Expansion Cohort 12 (ccRCC): Participants with unresectable advance or metastatic RCC with a clear cell component, including participants who also have a sacromatoid feature.

Must have received no more than two prior lines of systemic anticancer therapy for unresectable advanced or metastatic renal cell carcinoma
Expansion Cohort 13 and Cohort 14 (ccRCC 1L): Participants with unresectable advanced or metastatic RCC with a clear component, including participants who also have a sacromatoid feature.
Cohort 15 (mCRPC, post-ARPI, visceral metastases): Men with metastatic adenocarcinoma of the prostate.
Cohort 16 (Drug-drug interaction \[DDI\]):

Participants with a solid tumor that is unresectable or metastatic and for which life prolonging therapies do not exist or available therapies are intolerable or no longer effective.
Able to swallow capsules or tablets.
For all Expansion Cohorts except Cohort 3: Measurable disease per RECIST 1.1 as determined by the Investigator.
For Expansion Cohorts 1 - 11 Only: Archival tumor tissue material, if available, or fresh tumor tissue if it can be safely obtained.
Recovery to baseline or ≤ Grade 1 common terminology criteria for adverse events (CTCAE) v5 from AE(s) related to any prior treatments unless AE(s) are deemed clinically nonsignificant by the Investigator and/or stable on supportive therapy.
Karnofsky Performance Status (KPS) ≥ 70%.
Adequate organ and marrow function.
Sexually active fertile participants and their partners must agree to use highly effective methods of contraception.
Females of childbearing potential must not be pregnant at screening.

Key Exclusion Criteria:

For all Dose-Escalation cohorts: Prior treatment with zanzalintinib. For all Expansion Cohorts: Prior treatment with zanzalintinib, nivolumab, ipilimumab or relatlimab with the following exceptions: Prior PD-1/PD-L1, Lymphocyte-activation gene 3 (LAG-3) and cytotoxic T lymphocyte associated protein 4 (CTLA-4) targeting therapy for locally advanced or metastatic disease is allowed for Cohort 2 (ccRCC), Cohort 5 (UC), Cohort 9 (NSCLC), and Cohort 12 (ccRCC), and prior treatment in the neoadjuvant or adjuvant setting is allowed for Cohort 13 and Cohort 14 (ccRCC 1L).
For all Dose-Escalation Cohorts and Expansion Cohort 2 (ccRCC), 3 (mCRPC), Cohort 5 (UC), Cohort 9 (NSCLC), Cohort 10 (CRC), and Cohort 12: Receipt of any type of small molecule kinase inhibitor (including investigational kinase inhibitor) within 2 weeks before first dose of study treatment.
For Cohort 3 (mCRPC): Receipt of abiraterone within 1 week; cyproterone within 10 days; or receipt of flutamide, nilutamide, bicalutamide, enzalutamide, or other androgen receptor inhibitors within 2 weeks before first dose of study treatment.
For all Dose-Escalation Cohorts and Expansion Cohort 2 (ccRCC), Cohort 3 (mCRPC), Cohort 5 (UC), Cohort 9 (NSCLC) and Cohort 10 (CRC), and Cohort 12: Receipt of any type of anticancer antibody or systemic chemotherapy within 4 weeks before first dose of study treatment.
Any complementary medications (eg, herbal supplements or traditional Chinese medicines) to treat the disease under study within 2 weeks before first dose of study treatment.
Prior external radiation therapy for bone metastasis within 2 weeks, for other tumor sites within 4 weeks, and prior radium-223 therapy within 6 weeks before first dose of study treatment, unless otherwise specified.
Known brain metastases or cranial epidural disease unless adequately treated with radiotherapy and/or surgery (including radiosurgery) and stable for at least 4 weeks before first dose of study treatment.
Concomitant anticoagulation with oral anticoagulants, except for specified direct factor Xa inhibitors.
Administration of a live, attenuated vaccine within 30 days prior to first dose.
Uncontrolled, significant intercurrent or recent illness.
Corrected QT interval calculated by the Fridericia formula (QTcF) > 460 ms for females and > 450 ms for males per electrocardiogram (ECG) within 14 days before first dose of study treatment.
Participants with inadequately treated adrenal insufficiency.
Pregnant or lactating females.
Any other active malignancy within two years before first dose of study treatment, except for superficial skin cancers, or localized, low-grade tumors deemed cured and not treated with systemic therapy. Incidentally diagnosed prostate cancer is allowed if assessed as stage ≤ T2N0M0 and Gleason score ≤ 6.
For Cohort 2 (ccRCC, 2L): Receipt of a prior triplet therapy including a VEGFR-TKI, a PD1 targeting mAb, and a CTLA-4 mAb.
For Cohort 3 (mCRPC): Receipt of a taxane-based chemotherapy for mCRPC.
For Cohort 4 (UC, ICI-naïve): Participants who have had recurrence within the 6 months of completing adjuvant anti-PD-(L)1 treatment.
For Cohort 6 (nccRCC, 1L): Participants with chromophobe, renal medullary carcinoma, or pure collecting duct nccRCC.
For Cohort 7 (HCC):

Documented hepatic encephalopathy (HE) within 6 months before the first dose.
Clinically meaningful ascites (ie, ascites requiring paracentesis or escalation in diuretics) within 6 months before randomization.
Participants who have received any local anticancer therapy including surgery, percutaneous ethanol injection (PEI), radiofrequency ablation (RFA), microwave ablation (MWA), transarterial chemoembolization (TACE), or transarterial radioembolization (TARE) within 28 days prior to first dose.
Participants with known fibrolamellar carcinoma, sarcomatoid HCC, or mixed hepatocellular cholangiocarcinoma
For Cohort 10 (CRC, 2L+): Receipt of prior therapy with regorafenib and/or trifluridine + tipiracil (TAS-102).
For Cohort 11 (HNSCC): Primary tumor site of the nasopharyngeal area.
For Cohorts 1 (ccRCC, 1L), 2 (ccRCC, 2L), 4, 5 (UC), 7 (HCC), 8 (NSCLC 1L PD-L1 low), 9 (NSCLC, 2L+), 10 (CRC, microsatellite stable \[MSS\], 2L+), and 11 (HNSCC):

Troponin T (TnT) or I (TnI) > 2 × institutional upper limit of normal (ULN).
For Cohort 16 (DDI):

Known hypersensitivity to midazolam, warfarin, omeprazole, or caffeine.
History of major head trauma (with loss of consciousness) within the past year or minor head trauma (without loss of consciousness) within 3 months prior to first dose of study treatment on Day 1.
Primary liver tumor.
Unable to refrain from or anticipates the use of the following:

Any drugs known to be inducers or inhibitors of CYP3A4, CYP2C9, CYP2C19, and/or CYP1A2 within 14 days before the first dose of study treatment on Day 1 through the DDI assessments on Day 20.
Drugs that are contraindicated with midazolam, warfarin, omeprazole, and/or caffeine during the DDI assessment part.
Caffeine-containing beverages, products, and foods at least 3 days prior to and 3 days after probe substrate cocktail administration on Day 1 and Day 16.

Poor peripheral venous access.

Note: Additional Inclusion and Exclusion criteria may apply.

Study Design

Enrollment

1394 participants

Anticipated

Allocation

Randomized

Intervention Model

Sequential

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

experimental: Zanzalintinib + Nivolumab Dose-Escalation Cohorts

Approximately 12 participants will accrue across 1-2 dose levels of Zanzalintinib following the "rolling 6" design.

experimental: Zanzalintinib + Nivolumab + Ipilimumab Dose-Escalation Cohorts

Approximately 12 participants will accrue across 1-2 dose levels of Zanzalintinib following the "rolling 6" design.

experimental: Zanzalintinib + Nivolumab Expansion Cohorts

The recommended dose from the dose-escalation stage may be further explored in tumor-specific cohorts.

experimental: Zanzalintinib + Nivolumab + Ipilimumab Expansion Cohorts

The recommended dose from the dose-escalation stage may be further explored in tumor-specific cohorts.

experimental: Zanzalintinib Single-Agent Expansion Cohorts

experimental: Zanzalintinib + Nivolumab + Relatlimab Dose-Escalation Cohorts

Approximately 12 participants will accrue across 1-2 dose levels of Zanzalintinib following the "rolling 6" design.

experimental: Zanzalintinib + Nivolumab + Relatlimab Expansion Cohorts

The recommended dose from the dose-escalation stage may be further explored in tumor-specific cohorts.

experimental: Zanzalintinib + Docetaxel + Prednisone Dose Expansion Cohort

Participants with mCRPC, post-androgen receptor pathway inhibitor (post-ARPI), visceral metastases. The recommended dose from the dose-escalation stage may be further explored in tumor-specific cohorts.

experimental: Zanzalintinib + DDI Probe Substrates Dose Expansion Cohort

Participants in the DDI Cohort. The recommended dose from the dose-escalation stage may be further explored in tumor-specific cohorts.

Interventions

Zanzalintinib

Zanzalintinib orally once daily (qd)

Nivolumab

360 mg intravenous (IV) infusion once every 3 weeks (q3w)

Ipilimumab

1 mg/kg IV infusion once every 3 weeks (q3w) for maximum of four doses

Nivolumab

3 mg/kg IV infusion once every 3 weeks (q3w) for first four doses, and then 480 mg IV infusion once every 4 weeks (q4w)

Nivolumab

480 mg IV infusion once every 4 weeks (q4w)

Nivolumab + Relatlimab

IV administration of nivolumab + relatlimab

Prednisone

Administered as IV infusion.

Docetaxel

Administered as oral tablet.

DDI Probe Cocktail

Midazolam, Warfarin, Omeprazole, and Caffeine administered orally.

Primary outcome measure

Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs), Including Immune-Mediated Adverse Events (imAEs) [ Time Frame: Up to 36 months ]
Expansion Stage (All Cohorts Except Cohort 15 [mCRPC, post-ARPI, visceral metastases] and Cohort 16 [DDI]): Objective Response Rate (ORR) [ Time Frame: Up to 24 months ]
Expansion Stage Cohort 3 (mCRPC, post 1 NHT): Progression-Free Survival (PFS) [ Time Frame: Up to 24 months ]
Expansion Stage Cohort 10 (CRC): Overall Survival (OS) [ Time Frame: 6 months ]
Expansion Stage Cohort 15 (mCRPC, Post-ARPI, Visceral Metastases): PFS-6 (Six Month PFS) [ Time Frame: 6 months ]
Expansion Stage Cohort 16 (DDI): Area Under the Concentration-Versus-Time Curve (AUC) of Each DDI Probe Substrate With and Without Zanzalintinib [ Time Frame: Predose upto 8 hours postdose ]
Expansion Stage Cohort 16 (DDI): Maximum Concentration (Cmax) of Each DDI Probe Substrate With and Without Zanzalintinib [ Time Frame: Predose upto 8 hours postdose ]

Central Contacts and Locations

Central contacts

Exelixis Clinical Trials

1-888-EXELIXIS (888-393-5494)druginfo@exelixis.com

Backup or International

650-837-7400

Locations

Exelixis Clinical Site #67

Recruiting

Phoenix, Arizona, United States, 85054

Exelixis Clinical Site #1

Recruiting

Tucson, Arizona, United States, 85711

Exelixis Clinical Site #123

Recruiting

Palo Alto, California, United States, 94304

Exelixis Clinical Site #59

Recruiting

Santa Barbara, California, United States, 93463

Exelixis Clinical Site #87

Recruiting

Littleton, Colorado, United States, 80124

Exelixis Clinical Site #62

Recruiting

New Haven, Connecticut, United States, 06510

Exelixis Clinical Site #48

Recruiting

Celebration, Florida, United States, 34747

Exelixis Clinical Site #11

Recruiting

Gainesville, Florida, United States, 32610

Exelixis Clinical Site #78

Recruiting

Jacksonville, Florida, United States, 32224

Exelixis Clinical Site #47

Recruiting

Miami, Florida, United States, 33136

Exelixis Clinical Site #61

Recruiting

Plantation, Florida, United States, 33322

Exelixis Clinical Site #8

Recruiting

Tampa, Florida, United States, 33612

Exelixis Clinical Site #26

Recruiting

Chicago, Illinois, United States, 60612

Exelixis Clinical Site #4

Recruiting

Indianapolis, Indiana, United States, 46250

Exelixis Clinical Site #122

Recruiting

Louisville, Kentucky, United States, 40202

Exelixis Clinical Site #14

Recruiting

Baltimore, Maryland, United States, 21201

Exelixis Clinical Site #7

Recruiting

Boston, Massachusetts, United States, 02215

Exelixis Clinical Site #65

Recruiting

Detroit, Michigan, United States, 48201

Exelixis Clinical Site #13

Recruiting

Detroit, Michigan, United States, 48202

Exelixis Clinical Site #68

Recruiting

Rochester, Minnesota, United States, 55905

Exelixis Clinical Site #2

Recruiting

Omaha, Nebraska, United States, 68130

Exelixis Clinical Site #55

Recruiting

Las Vegas, Nevada, United States, 89052

Exelixis Clinical Site #88

Recruiting

East Brunswick, New Jersey, United States, 08816

Exelixis Clinical Site #105

Recruiting

Hackensack, New Jersey, United States, 07601

Exelixis Clinical Site #60

Recruiting

New York, New York, United States, 10032

Exelixis Clinical Site #6

Recruiting

New York, New York, United States, 10065

Exelixis Clinical Site #76

Recruiting

Syracuse, New York, United States, 13210

Exelixis Clinical Site #12

Recruiting

Durham, North Carolina, United States, 27710

Exelixis Clinical Site #10

Recruiting

Cleveland, Ohio, United States, 44106

Exelixis Clinical Site #51

Recruiting

Portland, Oregon, United States, 97239

Exelixis Clinical Site #104

Recruiting

Hershey, Pennsylvania, United States, 17033

Exelixis Clinical Site #98

Recruiting

Philadelphia, Pennsylvania, United States, 19104

Exelixis Clinical Site #32

Recruiting

Pittsburgh, Pennsylvania, United States, 15212

Exelixis Clinical Site #24

Recruiting

Pittsburgh, Pennsylvania, United States, 15232

Exelixis Clinical Site #9

Recruiting

Myrtle Beach, South Carolina, United States, 29572

Exelixis Clinical Site #3

Recruiting

Nashville, Tennessee, United States, 37203

Exelixis Clinical Site #46

Recruiting

Austin, Texas, United States, 78705

Exelixis Clinical Site #111

Recruiting

Dallas, Texas, United States, 75246

Exelixis Clinical Site #89

Recruiting

Dallas, Texas, United States, 75246

Exelixis Clinical Site #73

Recruiting

Irving, Texas, United States, 75063

Exelixis Clinical Site #50

Recruiting

Plano, Texas, United States, 75075

Exelixis Clinical Site #70

Recruiting

Tyler, Texas, United States, 75601

Exelixis Clinical Site #66

Recruiting

Charlottesville, Virginia, United States, 22903

Exelixis Clinical Site #33

Recruiting

Milwaukee, Wisconsin, United States, 53226

More Information

Sponsor

Exelixis

Last update posted

Aug 5, 2026

Last verified

Jul, 2026

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-08. This information was provided to ClinicalTrials.gov by Exelixis on 2026-08-05.